
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

**Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934**

For the month of May 2017

Commission File Number 001-37626

Mesoblast Limited

(Exact name of Registrant as specified in its charter)

Not Applicable

(Translation of Registrant's name into English)

Australia

(Jurisdiction of incorporation or organization)

Silviu Itescu

Chief Executive Officer and Executive Director

Level 38

55 Collins Street

Melbourne 3000

Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes No

INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K

On April 28, 2017, Mesoblast Limited filed with the Australian Securities Exchange a quarterly report for entities admitted on the basis of commitments (Appendix 4C) for the quarter ended March 31, 2017, which is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.

MESOBLAST LIMITED

/s/ Charlie Harrison

Charlie Harrison
Company Secretary

Dated: May 03, 2017

INDEX TO EXHIBITS

Item

99.1 Appendix 4C of Mesoblast Ltd, dated April 28, 2017.

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity
Mesoblast LimitedABN
68 109 431 870Quarter ended ("current quarter")
31 March 2017**Consolidated statement of cash flows**

	Current quarter US\$ '000	Year to date (9 months) US\$ '000
1 Cash flows from operating activities		
1.1 Receipts from customers	433	1,012
1.2 Payments for:		
(a) research and development	(15,089)	(36,643)
- research and development expenditure includes the incremental costs of the MPC-150-IM phase 3 program in advanced chronic heart failure through to the interim analysis as previously foreshadowed		
(b) manufacturing commercialisation	(2,484)	(15,071)
(c) advertising and marketing	—	—
(d) leased assets	—	—
(e) staff costs	(2,317)	(6,767)
(f) other expenses from ordinary activities	(3,337)	(9,036)
(g) other:		
- intellectual property portfolio expenses	(964)	(1,926)
- deposit with clinical research organisation in connection with the conduct of the chronic heart failure phase 3 trial, to be returned to Mesoblast on completion of the trial	(2,000)	(4,000)
1.3 Dividends received (see note 3)	—	—
1.4 Interest received	86	395
1.5 Interest and other costs of finance paid	—	—
1.6 Income taxes paid	—	—
1.7 Government grants and tax incentives	—	—
1.8 Other (provide details if material)	—	—
1.9 Net cash from / (used in) operating activities	(25,672)	(72,036)

	Current quarter US\$ '000	Year to date (9 months) US\$ '000
2 Cash flows from investing activities		
2.1 Payment to acquire:		
(a) property, plant and equipment	(22)	(314)
(b) businesses (see item 10)	—	—
(c) investments	—	—
(d) intellectual property	—	—
(e) other non-current assets	—	—
2.2 Proceeds from disposal of:		
(a) property, plant and equipment	—	—
(b) businesses (see item 10)	—	—
(c) investments	—	—
(d) intellectual property	—	—
(e) other non-current assets	—	—
2.3 Cash flows from loans to other entities	—	—
2.4 Dividends received (see note 3)	—	—
2.5 Other (provide details if material)	—	—
(a) Security deposits	453	453
2.6 Net cash from / (used in) investing activities	430	138
	Current quarter US\$ '000	Year to date (9 months) US\$ '000
3 Cash flows related to financing activities		
3.1 Proceeds from issues of shares	61,784	61,784
3.2 Proceeds from issue of convertible notes	—	—
3.3 Proceeds from exercise of share options	—	—
3.4 Transaction costs related to issues of shares, convertible notes or options	(1,824)	(1,884)
3.5 Proceeds from borrowings	—	—
3.6 Repayment of borrowings	—	—
3.7 Transaction costs related to loans and borrowings	—	—
3.8 Dividends paid	—	—
3.9 Other (provide details if material)	—	—
3.10 Net cash from / (used in) financing activities	59,960	59,900
	Current quarter US\$ '000	Year to date (9 months) US\$ '000
4 Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of quarter/year to date	33,902	80,937
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(25,672)	(72,036)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	430	138
4.4 Net cash from / (used in) financing activities (item 3.10 above)	59,960	59,900
4.5 Effect of movement in exchange rates on cash held	502	183
4.6 Cash and cash equivalents at end of quarter	69,122	69,122

+ See chapter 19 for defined terms.

	Current quarter US\$ '000	Previous quarter US\$ '000
5 Reconciliation of cash and cash equivalents		
at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts		
5.1 Bank balances	46,517	7,035
5.2 Call deposits	22,146	21,368
5.3 Bank overdrafts	—	—
5.4 Other (Term deposits)	459	5,499
5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)	69,122	33,902
		Current quarter US\$ '000
6 Payments to directors of the entity and their associates		
6.1 Aggregate amount of payments to these parties included in item 1.2		381
6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3		—
6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2		
<i>Payment to directors (for the current quarter) = \$381k</i>		
		Current quarter US\$ '000
7 Payments to related entities of the entity and their associates		
7.1 Aggregate amount of payments to these parties included in item 1.2		—
7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3		—
7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2		
<i>not applicable</i>		
		Current quarter US\$ '000
	Total facility amount at quarter end US\$ '000	Amount drawn at quarter end US\$ '000
8 Financing facilities available		
Add notes as necessary for an understanding of the position		
8.1 Loan facilities	—	—
8.2 Credit standby arrangements	—	—
8.3 Other (please specify)	—	—
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		
<i>not applicable</i>		

+ See chapter 19 for defined terms.

	US\$ '000
9	Estimated cash outflows for next quarter
9.1	Research and development (15,462)
	- research and development expenditure includes the incremental costs of the MPC-150-IM phase 3 program in advanced chronic heart failure.
9.2	Manufacturing commercialisation (3,985)
9.3	Advertising and marketing —
9.4	Leased assets —
9.5	Staff costs (2,022)
9.6	Other expenses from ordinary activities (3,215)
9.7	Other (provide details if material):
	(a) Intellectual property portfolio expenses (713)
	(b) deposit with clinical research organisation in connection with the conduct of the chronic heart failure phase 3 trial, to be returned to Mesoblast on completion of the trial (2,059)
9.8	Total estimated cash outflows (27,456)*

*Mesoblast is in advanced negotiations with selected pharmaceutical companies with respect to potential partnering of certain Tier 1 product candidates. If Mesoblast enters into a binding transaction in the next quarter, Mesoblast expects that one effect of the transaction is that its cash reserves are likely to increase. Mesoblast does not make any representation or give any assurance that such a binding transaction will be concluded.

In addition, Mesoblast expects its cash reserves to increase in the next quarter as we expect to receive the following income:

- the R&D tax incentive from the Australian Government;
- royalty income earned on sales of TEMCELL® HS Inj. in Japan, and
- interest income.

Mesoblast has established an equity facility for up to A\$120 million/US\$90 million over 36 months, to be used at its discretion to provide additional funds as required.

	Acquisitions US\$ '000	Disposals US\$ '000
10	Acquisitions and disposals of business entities	
	(items 2.1(b) and 2.2(b) above)	
10.1	—	—
10.2	—	—
10.3	—	—
10.4	—	—
10.5	—	—

+ See chapter 19 for defined terms.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here: /s/ Charlie Harrison Date: 28 April 2017
(Company Secretary)

Print name: Charlie Harrison

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

+ See chapter 19 for defined terms.